Antibodies to factor VIII in hemophilia A patients

Inhibitor development represents the main complication in the treatment of haemophilia A. The risk of inhibitor formation is in part genetically deter mined by the type of the underlying factor VIII gene lesion but environment al factors may also play an important role. Due to the lack of efficiency o f factor VIII in these patients other therapeutic agents must be used for t he treatment of bleedings, however, none is as effective as factor VIII in a non-inhibitor patient. Therefore, the eridication of the inhibitor throug h immune tolerance therapy is the treatment of choice. Centralized national and international immune tolerance registries have collected the results a nd show cost effectiveness of this treatment.